NCT01993329View on ClinicalTrials.gov

A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

February 20, 2014

Study Completion Date

February 28, 2014

Conditions
Asthma
Interventions
DRUG

Gefapixant 50 mg

Gefapixant 50 mg tablet administered orally

DRUG

Gefapixant 300 mg

Gefapixant 300 mg tablet administered orally

DRUG

Placebo to mimic 50 mg tablets

Sugar pill manufactured to mimic gefapixant 50 mg tablets

DRUG

Placebo to mimic 300 mg tablets

Sugar pill manufactured to mimic gefapixant 300 mg tablets

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01993329 - A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009) | Biotech Hunter | Biotech Hunter